AstraZeneca plc (LON:AZN) has been assigned a GBX 5,800 ($78.20) price objective by Berenberg Bank in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s target price suggests a potential upside of 18.08% from the company’s current price.

Several other research firms have also recently weighed in on AZN. Morgan Stanley reissued an “overweight” rating and set a GBX 5,600 ($75.50) price objective on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($69.44) price target on AstraZeneca plc and gave the company a “neutral” rating in a report on Tuesday, June 27th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Barclays PLC reaffirmed an “overweight” rating and issued a GBX 6,000 ($80.90) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of AstraZeneca plc in a report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average target price of GBX 5,041.09 ($67.97).

Shares of AstraZeneca plc (AZN) traded up 3.01% during midday trading on Tuesday, reaching GBX 4912.00. The company’s stock had a trading volume of 3,343,608 shares. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock’s market capitalization is GBX 62.18 billion. The stock’s 50-day moving average is GBX 4,574.46 and its 200 day moving average is GBX 4,884.61.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/24/berenberg-bank-analysts-give-astrazeneca-plc-azn-a-gbx-5800-price-target.html.

In related news, insider Nazneen Rahman acquired 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.